Netherlands· NL-b9a972a733de

Gemfibrozil Auro 600 mg, filmomhulde tabletten

A gemfibrozil product containing gemfibrozil, registered in Netherlands by Aurobindo Pharma B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC C10AB04

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about gemfibrozilAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Gemfibrozil is registered in 12 of 19 countries.

Countries holding a registration under ATC C10AB04 (gemfibrozil), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
6 of them publish a price we can compare per daily dose

Search gemfibrozil products by name

Gemfibrozil · ATC C10AB04

12 / 19 countries

Canada
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of gemfibrozil costs, country by country.

Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Gemfibrozil · price per daily dose (1.2 g)

USD · FX 28 Sept 2026

FR France$0.50
IT Italy$0.42

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: GEMFIBROZIL
Manufacturer: Aurobindo Pharma B.V.
Country: Netherlands (NL)
ATC code: C10AB04
ATC class: Gemfibrozil
Defined daily dose: 1.2 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
24878

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

165 interactions on record for gemfibrozil.

Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check gemfibrozil against other medicines How interaction checks work

Gemfibrozil · interactions on record

165 records

19 severe
57 moderate
2 minor
85 info

Most severe, free to view

LoperamideA07DA03severe
EluxadolineA07DA06severe
PioglitazoneA10BG03severe
RepaglinideA10BX02severe

2 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemfibrozil in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemfibrozil products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

Austria · Gevilon
Cyprus · Ipolipid, Lipofor
Denmark · Lopid
Spain · Gemfibrozilo Stada, Gemfibrozilo Tarbis
France · Lipur
United Kingdom (Northern Ireland) · Gemfibrozil Tillomed Laboratories, Lopid
Greece · Fibrolip, Gemlipid
Ireland · Lopid
Iceland · Lopid
Italy · Gemfibrozil Doc Generici, Gemfibrozil Eg
Portugal · Gemfibrozil Generis, Lopid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/c0685af2-08ac-4c02-a4f5-4301fcbbd498
GET /v1/drugs/c0685af2-08ac-4c02-a4f5-4301fcbbd498?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h24878_smpc.pdf",
  "strength": null,
  "atc_label": "Gemfibrozil",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg24878",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYSORBAAT 80 (E 433)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "GEMFIBROZIL"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h24878.pdf",
  "authorised_at": "2000/09/26",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "24878",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about gemfibrozil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console